Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Hepatocellular 61Stomach Neoplasms 46Carcinoma, Non-Small-Cell Lung 37Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Lung Neoplasms 12Rectal Neoplasms 11Nasopharyngeal Carcinoma 11Esophageal Neoplasms 11Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Cholangiocarcinoma 6Uterine Cervical Neoplasms 5Small Cell Lung Carcinoma 5Liver Neoplasms 5Triple Negative Breast Neoplasms 4Recurrence 4Endometrial Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Solid Tumor 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Carcinoma 3Breast Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × sintilimab × Clear all
NCT05572463 2022-11-18

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Withdrawn
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡